Athos, an au­toim­mune and can­cer biotech, is rais­ing $35M for clin­i­cal tri­als

Athos Ther­a­peu­tics is rais­ing a $35 mil­lion Se­ries B, it con­firmed to End­points News. The Tor­rance, CA-based biotech will de­ploy the mon­ey on its AI-based pre­ci­sion small mol­e­cules for au­toim­mune dis­eases and var­i­ous can­cer in­di­ca­tions.

About $10 mil­lion of the ex­pect­ed haul will go to­ward the lead as­set, an in­flam­ma­tion and mu­cos­al heal­ing-tar­get­ed treat­ment for in­flam­ma­to­ry bow­el dis­ease, CEO Dim­itrios Il­iopou­los said in an emailed state­ment. The biotech an­tic­i­pates Phase I topline da­ta by March and plans to start a Phase IIa by the third quar­ter of 2024, he added, not­ing the cap­i­tal will al­so fund it through that study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER